Ginkgo Bioworks Holdings Inc (NYSE:DNA)
$ 9.66 -0.56 (-5.48%) Market Cap: 587.43 Mil Enterprise Value: 367.95 Mil PE Ratio: 0 PB Ratio: 0.68 GF Score: 37/100

Q2 2024 Ginkgo Bioworks Holdings Inc Earnings Call Transcript

Aug 08, 2024 / 09:30PM GMT
Release Date Price: $11.43 (+4.15%)
Megan LeDuc;Jason Kelly<
Ginkgo Bioworks Holdings Inc - Manager, Investor Relations

Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. Thanks as always for joining us. We're looking forward to updating you on our progress.

As a reminder, during the presentation today, we will be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the SEC to learn more about these risks and uncertainties.

Today, in addition to updating you on the quarter, we are going to provide updates on our path towards adjusted EBITDA breakeven, including a deeper dive on how we're executing against our cost reduction targets as well as what we're doing to drive revenue. As usual, we'll end with a Q&A session, and I'll take questions from analysts, investors and the public. You can submit those questions to us in advance via X at #GinkgoResults results or e-mail investors at ginkgobioworks.com.

All right. Over to you, Jason.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot